Truist raises Axsome Therapeutics stock target to $190 on Symbravo approval

view original post

Truist Securities adjusted their financial outlook for Axsome Therapeutics (NASDAQ:AXSM), increasing the price target to $190 from the previous $180 while maintaining a Buy rating on the company’s …